The move reflects Nestl\u00e9\u2019s efforts to turn the rapid rise of GLP-1 medications from a potential threat into a major growth opportunity. <\/p>\n
What is Ozempic face?<\/p>\n
Ozempic face is the term used to describe either the puffiness from the effects of GLP-1 drugs or facial hollowness \u2013 sagging skin and increased wrinkles \u2013 from rapid fat loss.<\/p>\n
Innovating for GLP-1s<\/p>\n
The world\u2019s biggest CPG is using AI to process large volumes of clinical research and identify combinations of nutrients that support muscle health, hydration and nutritional intake.<\/p>\n
\u201cA big \u200bpart of weight loss is that people lose lean muscle mass,\u201d says Palzer. \u201cWe found a combination of two micronutrients which we industrialised that stimulate the growth of muscle tissue. On \u200bone hand you provide protein, on the other hand you stimulate the muscle tissue to grow back faster.\u201d<\/p>\n
Palzer says Nestl\u00e9 has also patented proprietary ingredient combinations for consumers coming off GLP-1 medications. The formulations are intended to help curb appetite as the drugs\u2019 effects fade, reducing the risk of rebound hunger and supporting weight management post-treatment.<\/p>\n
Alongside ingredient research, the Swiss giant\u2019s also using AI to simulate consumer behaviours and responses, \u200bidentify emerging trends, and identify reformulation opportunities within a database of roughly 120,000 recipes.<\/p>\n
![\"3D](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/08\/I3U5EAUKGREPHARUZEKWV5FCE4.jpg\")
The rapid rise of GLP-1 medications has sparked sales concerns across food and beverage. (Image: Getty\/Love Employee)GLP-1 threat or opportunity?<\/p>\n
Nestl\u00e9\u2019s latest move comes as food and beverage companies grapple with the implications of rapidly growing GLP-1 use.<\/p>\n
The rise of GLP-1 medications has sparked concerns across the food and beverage industry, with many analysts warning that appetite-suppressing drugs could fundamentally alter consumer eating habits.<\/p>\n
By reducing hunger and slowing gastric emptying, drugs such as Ozempic, Wegovy and Mounjaro can lead consumers to eat less, snack less frequently and become more selective about their food choices. For manufacturers whose growth has traditionally relied on volume sales, this presents a significant long-term challenge.<\/p>\n
Research has suggested GLP-1 users are more likely to cut back on discretionary purchases, particularly in categories such as salty snacks, sugary beverages and other indulgent products. At the same time, demand is expected to shift towards foods offering higher nutritional value, including products rich in protein, fibre and essential micronutrients.<\/p>\n
As a result, major food and beverage companies are increasingly reassessing their portfolios and innovation pipelines. And, like Nestl\u00e9, rather than viewing GLP-1s as a threat, many are now exploring ways to serve the growing number of consumers seeking products that support weight management, muscle retention and overall nutritional wellbeing while taking the drugs.<\/p>\n
As GLP-1 adoption continues to reshape eating habits and purchasing behaviour, the drugs are expected to exert an increasingly powerful influence on product development across the food and beverage sector, prompting more manufacturers to follow Nestl\u00e9\u2019s lead with targeted nutrition and reformulation strategies.<\/p>\n","protected":false},"excerpt":{"rendered":"Nestl\u00e9 GLP-1 nutrition strategy \u2013 overviewNestl\u00e9 is developing tailored nutrition products for GLP-1 usersScientists target muscle loss, dehydration…\n","protected":false},"author":2,"featured_media":116901,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[126],"tags":[17508,1716,56850,1717,56851,37409,15191,3751,56852,199,39806,56853,56854,9053,14989,56855],"class_list":["post-116900","post","type-post","status-publish","format-standard","has-post-thumbnail","category-nestle","tag-3d","tag-background","tag-biological","tag-concept","tag-counter","tag-educational","tag-innovative","tag-metabolic","tag-needle","tag-nestle","tag-oral","tag-presentation","tag-tablet","tag-therapy","tag-treatment","tag-type-2"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117116157841367331","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/116900","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=116900"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/116900\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/116901"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=116900"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=116900"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=116900"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}